Ramya Embar Srinivasan
Endocrinology, Diabetes & Metabolism · Alpharetta, GANPI 1720303241
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $649 and has fallen 50.2% since, to $323 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in GA, where the typical reported total is $2,873.
Across 88 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$348
- AbbVie$99
- Lilly USA, LLC$92
- Sanofi-aventis U.S. LLC$92
- Insulet Corporation$89
- Abbott$81
- plus $705 from 20 others
What the payments were for
- Food & beverage$1,47398%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $348 |
| AbbVie | 7 | $99 |
| Lilly USA, LLC | 6 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $92 |
| Insulet Corporation | 5 | $89 |
| Abbott | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Mannkind Corporation | 5 | $74 |
| Merck | 5 | $69 |
| Medtronic | 3 | $54 |
| Valeritas, Inc. | 2 | $51 |
| Amgen | 2 | $37 |
| IBSA Pharma Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $33 |
| Boehringer Ingelheim | 2 | $33 |
| AstraZeneca | 2 | $32 |
| Corcept Therapeutics | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Pfizer | 1 | $20 |
| Bayer | 1 | $19 |
| BD | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$1,506 in reported general payments places this provider in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $218 |
| Amlodipine Besylate | 11 | $183 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Alpharetta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.